Scienture Holdings Inc (SCNX)

$2.01 +0.02 (1.01%)
Market Cap 26.10M
Revenue (ttm) 140,000.00
Net Income (ttm) 9.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 6,478.57%
Debt to Equity Ratio 0.01
Volume 110,700
Avg Vol 176,388
Day's Range N/A - N/A
Shares Out 13.12M
Stochastic %K 57%
Beta 2.88
Analysts Strong Buy
Price Target N/A

Company Profile

Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN...

Industry: Pharmaceutical Retailers
Sector: Healthcare
Phone: 800 261 0281
Address:
6308 Benjamin Rd, Suite 708, Tampa, United States
paideia
paideia Jul. 28 at 6:01 PM
$SCNX Even though Rezenopy is available only by prescription, aren't police, EMTs, Hospitals, fire departments all over the country going to prefer having it? How's that going to work?
0 · Reply
Li9999
Li9999 Jul. 28 at 1:55 PM
$SCNX I’m out since Mar 18 ,2023 , sorry everyone here
0 · Reply
stockinvestbull
stockinvestbull Jul. 28 at 8:55 AM
$SCNX It's rising nicely. There's still room to go up. 📈
0 · Reply
Supporter67
Supporter67 Jul. 26 at 3:30 PM
$SLS I‘m convinced they will need money. A financing is not a problem as long as you do it smart. Not like in the past. Look at $SCNX. They did a bridge financing last week. No toxic warrant. No sweetener at all. They sold shares directly to one institutional client. $SLS did very bad financings in the past. As if Anson or Highbridge would have something in the hand against Angelos. Like the Epstein filed.
1 · Reply
BinaryLogic
BinaryLogic Jul. 26 at 1:57 AM
$SCNX $ALT $EBS $MIST $NVAX
2 · Reply
BinaryLogic
BinaryLogic Jul. 26 at 1:57 AM
$SCNX [Again] Liquidity remains the issue here, and the Company if on queue issues a very limited placement to specific investors (enumerated in the PR) for $1.2M with the possibility of scaling to $3.0M at a $1.59 strike. This is Bullish (IMO). The Liquidity issue is being addressed, there is limited impact to shareholders, the $1.59 strike is a marked premium from just 1mos ago, and this implies the Company does not require much stop-gap funding (hopefully) before administering NWC and debt organically (sales/FCF). The SP might retrace further to either the Bull flag support ($1.8) or investor ($1.6), and I will continue to DCA into the pull back. RSI cooling, pull-back to support awaiting Arbli sales and Rezenopy launch. Multiplier upside from this level (IMO), 6-12mos. https://www.stocktitan.net/news/SCNX/
2 · Reply
pAmdd
pAmdd Jul. 25 at 6:19 PM
$SCNX they don’t have money to start production and marketing of the drug 3 million is absolutely nothing they will run this company into the ground
1 · Reply
APEDM
APEDM Jul. 25 at 5:22 PM
$SCNX Many people sold at 1.9-2
0 · Reply
JackCampbell
JackCampbell Jul. 25 at 3:21 PM
$SCNX the way how they raise funds is excellent for us shareholders. Only if needed from time to time and in smallest tranches and hopefully much higher share prices each. Investors swoop up all new available shares instantly as they are very confident to multiple their investment here. Double digits soon!!!
1 · Reply
DW65
DW65 Jul. 25 at 2:15 PM
$SCNX perfect time to be bought up by one of the big dogs
2 · Reply
Latest News on SCNX
Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Jul 24, 2025, 5:12 PM EDT - 4 days ago

Scienture Holdings, Inc. Obtains $1.2 Million in Bridge Funding

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Jul 16, 2025, 8:15 AM EDT - 12 days ago

Scienture Holdings, Inc. Regains Compliance with Nasdaq Listing Requirements

Scienture Holdings Announces Cancelation of ELOC

Jun 17, 2025, 8:05 AM EDT - 5 weeks ago

Scienture Holdings Announces Cancelation of ELOC

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

May 28, 2025, 7:45 AM EDT - 2 months ago

Wellgistics Health Strengthens Executive Team and Board with Strategic Appointments to Accelerate Scale and Drive Shareholder Value

WGRX

SCIENTURE Announces Executive Leadership Transition

May 22, 2025, 8:05 AM EDT - 2 months ago

SCIENTURE Announces Executive Leadership Transition

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

May 19, 2025, 8:05 AM EDT - 2 months ago

SCIENTURE announces FDA Orange Book Patent Listing for ArbliTM, (losartanpotassium) Oral Suspension, 10mg/mL.

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

Apr 22, 2025, 8:05 AM EDT - 3 months ago

SCIENTURE announces manufacturing and supply chain readiness for ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL for a target product launch in July 2025.

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Apr 8, 2025, 8:05 AM EDT - 3 months ago

SCIENTURE announces the divestiture of its legacy subsidiaries for a total consideration of $5 million and dedicates its full focus to the Branded and Specialty Pharma segment through Scienture, LLC.

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

Apr 3, 2025, 8:26 AM EDT - 4 months ago

Scienture Holdings, Inc. Issues Annual Letter to Shareholders

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Mar 25, 2025, 8:05 AM EDT - 4 months ago

SCIENTURE Announces Commercial Operations Leadership and Strategic Agreement with Syneos Health, a leading Contract Sales Organization

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

Mar 19, 2025, 8:05 AM EDT - 4 months ago

Scienture Holdings Announces Draw on ELOC, Temporarily Suspends Further Draws Until Reaching $10/Share or 30 Trading Days

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

Mar 18, 2025, 8:05 AM EDT - 4 months ago

SCIENTURE announces the U.S. FDA Approval of its NDA for SCN-102, to be launched as ArbliTM, (losartan potassium) Oral Suspension, 10mg/mL. The global market for losartan potassium was approximately $1.5 billion in sales in 2024.

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Mar 6, 2025, 7:40 AM EST - 5 months ago

SCIENTURE to commercially launch REZENOPY®, a life-saving opioid overdose emergency treatment through a collaboration with KINDEVA DRUG DELIVERY L.P.

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Jan 21, 2025, 8:05 AM EST - 6 months ago

Scienture Holdings, Inc. Announces Dr. Narasimhan Mani's Participation in the 8th Annual Conference of The Society for the Study of Xenobiotics

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Dec 17, 2024, 8:05 AM EST - 7 months ago

Scienture Holdings, Inc. Announces Participation in The Microcap Conference 2025

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

Dec 10, 2024, 8:05 AM EST - 8 months ago

Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

Sep 24, 2024, 8:01 AM EDT - 10 months ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. and Ticker Symbol Change to “SCNX”

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

Sep 20, 2024, 11:59 AM EDT - 11 months ago

TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc.

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

Aug 5, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces New Addition and Changes to Scienture, LLC's Executive Leadership Team

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

Jul 26, 2024, 8:01 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million

TRxADE Health, Inc. Announces Special Cash Dividend

Jul 9, 2024, 8:05 AM EDT - 1 year ago

TRxADE Health, Inc. Announces Special Cash Dividend

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

May 29, 2024, 4:05 PM EDT - 1 year ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Apr 23, 2024, 4:05 PM EDT - 1 year ago

TRxADE Health, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K

Trxade health, Inc files its 3Q 10Q

Jan 17, 2024, 9:07 AM EST - 1 year ago

Trxade health, Inc files its 3Q 10Q

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

Nov 29, 2023, 6:13 PM EST - 1 year ago

TRxADE Announces Receipt of Notification of Deficiency from Nasdaq Regarding Requirement to Timely File Quarterly Report on Form 10-Q.

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Oct 17, 2023, 8:05 AM EDT - 1 year ago

TrxADE Health, Inc. affirms its commitment to the pharmaceutical space via its subsidiary Trxade, Inc. which operates the pharmaceutical marketplace and added more members in the third quarter of 2023.

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Oct 12, 2023, 8:05 AM EDT - 1 year ago

Superlatus Announces Distribution Partnership with North America's Leading Wholesale Distributor and Expanded Points of Retail Sales

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

Oct 4, 2023, 8:05 AM EDT - 1 year ago

Superlatus, Newly Merged with TRxADE HEALTH, Acquires the assets of Spero Foods, a plant-based tech company Disrupting the Dairy and Egg Industry.

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.

Sep 7, 2023, 9:00 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, Is Gearing Up To Make Big Splashes In the $151 Billion Snacks Industry with its Acquisition of The Urgent Company Inc.

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market

Sep 6, 2023, 9:45 AM EDT - 2 years ago

TRxADE Health (NASDAQ:MEDS), Newly Merged With Superlatus, To Acquire The Urgent Company to Expand its Reach In The Sustainable Foods Market

Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand

Aug 24, 2023, 8:05 AM EDT - 2 years ago

Superlatus Innovates $151 Billion US Snacking Market with Pulse-Based Protein Twists Under the Brave Robot Brand

Superlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc.

Aug 22, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Newly Merged with TRxADE HEALTH, Agrees to Acquire The Urgent Company, Inc. and its portfolio of Consumer Brands from Perfect Day, Inc.

TRxADE HEALTH, Inc. Announces Extension of Form 10-Q Filing

Aug 14, 2023, 10:25 AM EDT - 2 years ago

TRxADE HEALTH, Inc. Announces Extension of Form 10-Q Filing

Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team

Aug 3, 2023, 9:05 AM EDT - 2 years ago

Newly merged Entity Superlatus, Inc with Trxade Health, Inc. Appoints Leading CPG Management Team

TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m.

Jul 31, 2023, 4:15 PM EDT - 2 years ago

TRxADE HEALTH, INC. to Report Q2 2023 Financial Results on Monday, August 14th at 6:00 p.m.

TRxADE HEALTH, Inc. Announces Closing of Acquisition of Superlatus, Inc.

Jul 31, 2023, 8:35 AM EDT - 2 years ago

TRxADE HEALTH, Inc. Announces Closing of Acquisition of Superlatus, Inc.

TRxADE HEALTH, Inc. Amends Definitive Merger Agreement with Superlatus, Inc.

Jul 14, 2023, 4:30 PM EDT - 2 years ago

TRxADE HEALTH, Inc. Amends Definitive Merger Agreement with Superlatus, Inc.

Superlatus, Inc. and TRxADE HEALTH, Inc. Sign Definitive Merger Agreement to Create a Global Strategic Platform for Food and Healthy Snack Marketplace and Distribution

Jun 30, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Inc. and TRxADE HEALTH, Inc. Sign Definitive Merger Agreement to Create a Global Strategic Platform for Food and Healthy Snack Marketplace and Distribution

TRxADE HEALTH, Inc. Issues Correction to Press Release Announcing its Anticipated Combination with Superlatus, Inc. (Correction Notice)

Jun 23, 2023, 4:40 PM EDT - 2 years ago

TRxADE HEALTH, Inc. Issues Correction to Press Release Announcing its Anticipated Combination with Superlatus, Inc. (Correction Notice)

EAT WELL GROUP TO SELL SAPIENTIA FOR USD $10 MILLION IN NASDAQ MERGER WITH MEDS & SUPERLATUS FOODS

Jun 23, 2023, 3:00 PM EDT - 2 years ago

EAT WELL GROUP TO SELL SAPIENTIA FOR USD $10 MILLION IN NASDAQ MERGER WITH MEDS & SUPERLATUS FOODS

Superlatus, Inc. to Combine with TRxADE HEALTH, Inc., to Create a Global Food Consolidation Platform

Jun 23, 2023, 8:05 AM EDT - 2 years ago

Superlatus, Inc. to Combine with TRxADE HEALTH, Inc., to Create a Global Food Consolidation Platform

TRxADE Health, Inc.'s Board of Directors Approves Reverse Stock Split

Jun 21, 2023, 12:36 PM EDT - 2 years ago

TRxADE Health, Inc.'s Board of Directors Approves Reverse Stock Split

TRxADE HEALTH, Inc. (MEDS) Q1 2023 Earnings Call Transcript

May 15, 2023, 10:30 PM EDT - 2 years ago

TRxADE HEALTH, Inc. (MEDS) Q1 2023 Earnings Call Transcript

TRxADE HEALTH Reports First Quarter Gross Margin of 69% and Q1 2023 Financial Results

May 15, 2023, 5:00 PM EDT - 2 years ago

TRxADE HEALTH Reports First Quarter Gross Margin of 69% and Q1 2023 Financial Results

TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 15th at 6:00 p.m.

May 5, 2023, 4:15 PM EDT - 2 years ago

TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 15th at 6:00 p.m.

TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 8th at 5:00 p.m.

Apr 25, 2023, 12:20 AM EDT - 2 years ago

TRxADE HEALTH, INC. to Report Q1 2023 Financial Results on Monday, May 8th at 5:00 p.m.

TRxADE HEALTH, Inc. (MEDS) Q4 2022 Earnings Call Transcript

Mar 27, 2023, 9:30 PM EDT - 2 years ago

TRxADE HEALTH, Inc. (MEDS) Q4 2022 Earnings Call Transcript

TRxADE HEALTH Reports 16% Revenue Growth and Year End 2022 Financial Results

Mar 27, 2023, 4:30 PM EDT - 2 years ago

TRxADE HEALTH Reports 16% Revenue Growth and Year End 2022 Financial Results

TRxADE HEALTH, INC. to Report Q4 and Year-End 2022 Financial Results on Monday, March 27th at 5:30 p.m.

Mar 13, 2023, 4:00 PM EDT - 2 years ago

TRxADE HEALTH, INC. to Report Q4 and Year-End 2022 Financial Results on Monday, March 27th at 5:30 p.m.

Bonum Health(TM), LLC (a TRxADE HEALTH Company) Reaffirms its Commitment to Independent Pharmacies and Group Purchasing Organizations (GPOs) with its Novel Telemedicine Services Model

Dec 6, 2022, 9:00 AM EST - 2 years ago

Bonum Health(TM), LLC (a TRxADE HEALTH Company) Reaffirms its Commitment to Independent Pharmacies and Group Purchasing Organizations (GPOs) with its Novel Telemedicine Services Model

paideia
paideia Jul. 28 at 6:01 PM
$SCNX Even though Rezenopy is available only by prescription, aren't police, EMTs, Hospitals, fire departments all over the country going to prefer having it? How's that going to work?
0 · Reply
Li9999
Li9999 Jul. 28 at 1:55 PM
$SCNX I’m out since Mar 18 ,2023 , sorry everyone here
0 · Reply
stockinvestbull
stockinvestbull Jul. 28 at 8:55 AM
$SCNX It's rising nicely. There's still room to go up. 📈
0 · Reply
Supporter67
Supporter67 Jul. 26 at 3:30 PM
$SLS I‘m convinced they will need money. A financing is not a problem as long as you do it smart. Not like in the past. Look at $SCNX. They did a bridge financing last week. No toxic warrant. No sweetener at all. They sold shares directly to one institutional client. $SLS did very bad financings in the past. As if Anson or Highbridge would have something in the hand against Angelos. Like the Epstein filed.
1 · Reply
BinaryLogic
BinaryLogic Jul. 26 at 1:57 AM
$SCNX $ALT $EBS $MIST $NVAX
2 · Reply
BinaryLogic
BinaryLogic Jul. 26 at 1:57 AM
$SCNX [Again] Liquidity remains the issue here, and the Company if on queue issues a very limited placement to specific investors (enumerated in the PR) for $1.2M with the possibility of scaling to $3.0M at a $1.59 strike. This is Bullish (IMO). The Liquidity issue is being addressed, there is limited impact to shareholders, the $1.59 strike is a marked premium from just 1mos ago, and this implies the Company does not require much stop-gap funding (hopefully) before administering NWC and debt organically (sales/FCF). The SP might retrace further to either the Bull flag support ($1.8) or investor ($1.6), and I will continue to DCA into the pull back. RSI cooling, pull-back to support awaiting Arbli sales and Rezenopy launch. Multiplier upside from this level (IMO), 6-12mos. https://www.stocktitan.net/news/SCNX/
2 · Reply
pAmdd
pAmdd Jul. 25 at 6:19 PM
$SCNX they don’t have money to start production and marketing of the drug 3 million is absolutely nothing they will run this company into the ground
1 · Reply
APEDM
APEDM Jul. 25 at 5:22 PM
$SCNX Many people sold at 1.9-2
0 · Reply
JackCampbell
JackCampbell Jul. 25 at 3:21 PM
$SCNX the way how they raise funds is excellent for us shareholders. Only if needed from time to time and in smallest tranches and hopefully much higher share prices each. Investors swoop up all new available shares instantly as they are very confident to multiple their investment here. Double digits soon!!!
1 · Reply
DW65
DW65 Jul. 25 at 2:15 PM
$SCNX perfect time to be bought up by one of the big dogs
2 · Reply
TomMac64
TomMac64 Jul. 25 at 2:12 PM
$SCNX They are low in cash !
0 · Reply
APEDM
APEDM Jul. 25 at 2:02 PM
$SCNX Scienture Announces Manufacturing Launch Activities For Arbli Through Subsidiary Scienture, In Collaboration With Saptalis Pharmaceuticals And Strategic Distribution Partners, Targeting July 2025 Commercial Launch
0 · Reply
Li9999
Li9999 Jul. 25 at 11:37 AM
$SCNX SCN-102 (losartan oral suspension) – FDA-approved and launches expected in Q3 2025 under the brand name Arbli™
0 · Reply
APEDM
APEDM Jul. 25 at 7:17 AM
$SCNX https://www.sec.gov/Archives/edgar/data/1382574/000164117225020877/form8-k.htm https://www.sec.gov/Archives/edgar/data/1382574/000164117225020877/ex99-1.htm
0 · Reply
PoFolks_Capital
PoFolks_Capital Jul. 25 at 3:15 AM
$SCNX been here since march and since then the bearish talk was dilution from the eloc. Now they canceled the eloc which should signal they have other plans besides dilution. Everyone can keep looking for something negative to push but at this point it doesn't matter. Buyers have been pushing it up and that's all the bullish news you need to know right now.
0 · Reply
chubbypapa
chubbypapa Jul. 25 at 1:18 AM
$SCNX I entered on 1.9, and July is about to pass. Are they facing any difficulties?
0 · Reply
Trash_Man
Trash_Man Jul. 24 at 11:29 PM
$SCNX I was able to get partial fill at the 1.93 dip. Did anyone take advantage of the dip?
0 · Reply
FilingTracker
FilingTracker Jul. 24 at 9:24 PM
$SCNX Capital raise was at $1.59/share: https://www.sec.gov/Archives/edgar/data/1382574/000164117225020877/form8-k.htm
3 · Reply
AmoredBull24
AmoredBull24 Jul. 24 at 6:08 PM
$SCNX Slow and Steady , with the 3rd qtr of 2025 we should see more climb to 3+ imo
0 · Reply
AmoredBull24
AmoredBull24 Jul. 24 at 6:05 PM
$SCNX its up 100% in a month lol
1 · Reply
AmoredBull24
AmoredBull24 Jul. 24 at 6:02 PM
$SCNX lets go
0 · Reply
pAmdd
pAmdd Jul. 24 at 5:10 PM
$SCNX told you this one is dead money
0 · Reply